Key Highlights
- AIM Penny Stock rose 6.18% pre-market to $0.25, reversing a 0.59% decline in the prior session.
- The company secured three forms of Patent protection across Europe and the UK for its drug's use in treating Long COVID.
- Patent protection is expected to extend through June 2041.
- The nine-month opposition period for the European patent closed August 25, 2026, with no opposition filed.
- The news follows a separate newly issued US patent covering the drug in combination with an approved cancer immunotherapy.
European Patent Estate Expands for Long COVID Indication
AIM ImmunoTech (NYSE American:AIM) penny stock rose in pre-market trading after the company announced expanded patent protection across 18 European countries and the United Kingdom for its drug Ampligen in treating Long COVID, the persistent post-viral symptoms some patients experience following COVID-19 infection. The patent protection is expected to run through June 2041.
AIM ImmunoTech is an Ocala, Florida-based immuno-pharma company focused on researching and developing therapies for cancers, viral diseases, and immune-deficiency disorders. Its lead investigational drug is being studied across a range of conditions including pancreatic cancer, chronic fatigue syndrome, and post-COVID conditions.
Patent Covers Multiple Dosing and Delivery Methods
The granted claims cover the drug's use in treating Long COVID patients through several delivery methods, including intranasal, intravenous, and inhalation administration, along with specific dosing regimens. The company noted that its drug has been tested in more than 1,200 patients across over 100,000 doses, with no drug-related deaths reported to date.
AIM carries a market Capitalization of roughly $798,000, reflecting its penny stock status and early-stage commercial position. The company does not currently generate significant Revenue from approved products, with its lead drug still under investigation across most of its target indications.
Follows Recent US Cancer Combination Patent Win
The European and UK patent grants come shortly after the company secured a separate US patent covering its drug's use in combination with a widely used cancer immunotherapy for treating cancer. Together, the two patent developments expand the company's intellectual property coverage across multiple therapeutic areas and major global markets.
Clinical Data and Regulatory Path Remain Key Catalysts Ahead
While the expanded patent estate strengthens the company's long-term intellectual property position, the drug remains investigational across its targeted indications, including Long COVID and cancer. Investors will watch for future clinical trial results and any regulatory developments as the next catalysts for the stock.






Please wait processing your request...